| 摘要 |
Heterocyclic-substituted tricyclics of the formula or a pharmaceutically acceptable salt thereof, wherein: the dotted line represents an optional single bond; <img id="custom-character-00001" he="2.79mm" wi="7.03mm" file="US20070270439A1-20071122-P00002.TIF" img-content="character" img-format="tif"/>represents an optional double bond; n is 0-2; Q is cycloalkyl, optionally substituted by R<SUP>13 </SUP>and R<SUP>14</SUP>; R<SUP>13 </SUP>and R<SUP>14 </SUP>are independently selected from (C<SUB>1</SUB>-C<SUB>6</SUB>)alkyl, (C<SUB>3</SUB>-C<SUB>8</SUB>)cycloalkyl, -OH, (C<SUB>1</SUB>-C<SUB>6</SUB>)alkoxy, R<SUP>27</SUP>-aryl(C<SUB>1</SUB>-C<SUB>6</SUB>)alkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halogen and haloalkyl; or R<SUP>13 </SUP>and R<SUP>14 </SUP>together form a spirocyclic or a heterospirocyclic ring of 3-6 atoms; Het is a mono- or bi-cyclic optionally substituted heteroaryl group; and B is a bond, alkylene, or optionally substituted alkenylene or alkynylene, wherein the remaining substituents are as defined in the specification, are disclosed, as well as pharmaceutical compositions containing them and a method of treating diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, and cancer by administering said compounds. Combination therapy with other cardiovascular agents is also claimed.
|
